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We compared the Swedish Coronary Angiography and
Angioplasty Registry with the Swedish ‘Hospital Discharge
Register’ to assess contrast media (CM)-induced renal failure.
Hospitals used only one type CM. From 2000 to 2003,
iodixanol (iso-osmolar) was used in 45 485 patients, ioxaglate
(low osmolar) in 12 440 subjects. To include the earlier used
CM iohexol (low osmolar), analysis extended back to 1990
(86 334 patients). Incidence of clinically significant renal
failure was greatest for patients receiving the iso-osmolar
CM iodixanol (1.7%). Ioxaglate-treated patients had a
significantly lower renal failure incidence (0.8%, Po0.001).
The odds ratio for iodixanol-treated patients was significantly
higher than for ioxaglate (1 vs 0.48, Po0.001). In subsets
of either diabetic patients or patients with previous renal
failure, odds ratios for renal failure remained greater in
the iodixanol groups (Po0.01). Hospitals switching CM to
iodixanol experienced a doubling in clinically significant
renal failure after cardiac procedures. Dialysis was required in
0.2% of patients receiving iodixanol, which was significantly
higher (Po0.01) than for ioxaglate-treated patients (0.1%).
Iohexol-treated patients had a similar low risk for developing
clinically significant renal failure (0.9%) as ioxaglate. In
conclusion, risk of developing renal failure and required
dialysis after coronary procedures is higher when patients
received iodixanol than ioxaglate or iohexol.
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Owing to the large number of investigations requiring
contrast media (CM), contrast-induced nephropathy (CIN)
is one of the most common causes of acquired acute renal
failure in the hospital environment (for recent review see
Tepel et al.1), thus causing considerable in-hospital morbidity
and mortality.2,3 The definition of CIN varies. One defini-
tion4,1 is a condition in which:
K An increase in serum creatinine occurs within 3
days following the intravascular administration of a
CM
K Increases in serum creatinine are greater than 25%
or 44 mmol/l (0.5 mg/dl)
K There is no alternative etiology.
During the usual course of CIN, serum creatinine returns
to normal values within 1–3 weeks. The risk for developing
CIN in patients with mild-to-moderate chronic renal
insufficiency ranges between the studies from below 5% to
more than 30%.5 However, the likelihood for actually
developing renal failure is considered to be much less
(o1%).6 Indeed, renal failure following CM administration
is a rare event,7 much lower than CIN.8 The occurrence is so
low that in most studies CIN is used as a surrogate marker for
renal failure.
In this report, we seek to provide data on the occurrence
of clinically significant renal failure for two different CM that
were given during coronary procedures (coronary angiogra-
phies and percutaneous coronary interventions (PCI)). The
present study includes over 57 000 patients from 23 hospitals
in Sweden and does not rely on serum creatinine concentra-
tions as a marker for the potential development of renal
failure. Instead, the incidence of kidney damage is assessed by
the re-hospitalization of these patients with a diagnosis of
renal failure, or by required dialysis.
Patients at risk, for example, diabetic patients and patients
with previous renal failure were also evaluated separately.
This was carried out to avoid the influence of unequal
distribution of these variables.
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Moreover, in an additional analysis, we extended the
observation period to include a third CM, iohexol that was
commonly used in the 1990s. However, to avoid a time effect,
the primary analysis was restricted to the years 2000–2003.
During this time period, the percentage use of iodixanol and
ioxaglate was stable.
The three investigated CM have different physico-
chemical properties (Table 1). Iodixanol is an iso-osmolar
compound, but has greater viscous properties. Iohexol has a
considerably higher osmolality than plasma (but is referred
to as a low-osmolar compound, as the osmolality is less than
half as high as the pioneer CM). Ioxaglate is an ionic CM
with similar osmolar and viscous properties as iohexol.
Aspelin et al.9 showed in the NEPHRIC study that in 129
diabetic patients iso-osmolar iodixanol is much less likely to
cause CIN than the low-osmolar agent iohexol. The
NEPHRIC study used an increase in plasma creatinine to
define CIN. In the accompanying editorial to the NEPHRIC
study, Sandler10 concluded that the results of NEPHRIC are
encouraging, however, one should not yet conclude that
iodixanol is the answer to contrast-agent-induced acute renal
dysfunction and that we will have to depend on clinical
studies to further elucidate this important problem. In
contrast to NEPHRIC, the present study shows that iodixanol
causes a higher incidence of clinically significant renal failure
and dialysis than ioxaglate or iohexol.
RESULTS
Analysis 2000–2003 (groups 1–5)
Owing to the large group sizes, even minor differences in
many known cofactors11 can reach statistical significance
(Table 2).
Figure 1 depicts the cumulative occurrence of clinically
significant renal failure and dialysis. The values indicated on
the y axis refer to the percentage of all patients that developed
clinically significant renal failure at a certain time.
As can be seen, clinically significant renal failure after PCI
or coronary angiography is uncommon (Table 3, Figure
1a–c), well below 1% of discharged patients during the first
week had experienced clinically significant renal failure after
the coronary procedure. This is different in patients that had
previously been diagnosed with renal failure (Figure 1d). In
those patients that experienced renal failure before in life,
reoccurrence of renal failure was observed in well over 30% of
the patients.
Giving iodixanol instead of ioxaglate increased the
occurrence of clinically significant renal failure markedly.
This difference was seen both for the primary diagnosis of
clinically significant renal failure (Table 3, Figure 1a) and for
the total (primary and secondary) diagnosis (Table 3, Figure
1b). Primary diagnosis of renal failure means that the main
reason for the patient being treated was failure of the kidney.
Secondary diagnosis means that other causes than renal
failure were the predominant reason for treating the patient,
but that renal failure was diagnosed during this treatment
period. In accord with clinically significant renal failure, the
need for subsequent dialysis following coronary procedures
was significantly greater for the iodixanol-treated patients
(Figure 1c, Tables 2 and 3): For patients leaving a clinic
within 1 month after PCI using ioxaglate, only 0.02%
required dialysis. The value for the iodixanol-treated patients
was fivefold higher (Po0.01).
Table 1 | Physico-chemical properties of the CM for an iodine concentration of 320 mg/ml, at 371C
Principal structure Ionicity
Iodine concentration
(mg/ml)
Osmolality
(mOsm/kgH2O)
Viscosity at 371C
(mPa/s)
Iodixanol Dimer Nonionic 320 290 11.4
Ioxaglate Dimer Ionic 320 600 7.5
Iohexol Monomer Nonionic 320 740 6.4
CM, contrast media.
Data as provided by the compound specifications of the producers. In order to present values for an equivalent iodine concentration (320 mg/ml), the function curves were
derived for various concentrations of CM. The interpolated values for 320 mg/ml were then taken.
Table 2 | Distribution of cofactors among the clinics using the
various CM
Background characteristics
Time period
2000–2003
Variable Ioxaglate Iodixanol P-value
n 12 440 45 485
Age (mean7s.d., years) 64.8710.7 64.4711.1 0.003
Female gender (%) 33.1 32.2 0.047
Diabetes o0.001
Yes (%) 18.5 16.6
Unknown (%) 14.0 6.4
Previous PCI/cor angio (%) 27.1 27.6 NS
Indication o0.001
STEMI (%) 6.9 7.7
Unstable CAD (%) 34.8 36.9
Stable CAD (%) 36.7 38.9
Other (%) 21.6 16.5
PCI (%) 44.7 41.3 o0.001
Stenting 84.9% 82.2% o0.001
Stents/PCI 1.21 1.20 NS
Previous renal failure (%) 0.78 1.26 o0.001
Previous dialysis (%) 0.57 0.67 NS
CAD, coronary artery disease; CM, contrast media; cor angio, coronary angiography;
NS, nonsignificant; PCI, percutaneous coronary interventions; s.d., standard
deviation; STEMI, Stelevation myocardial ifarction.
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A center that switched CM is shown separately (Figure
1e). After changing CM to iodixanol, the risk to develop
clinically significant renal failure within 3 months became
significantly higher in the iodixanol (2.1%) compared to the
ioxaglate patients (0.7%), Po0.001.
When only looking at the diabetic patients that are at
higher risk for developing renal failure, the differences
between the two CM groups remain. Ioxaglate caused less
clinically significant renal failure in the high-risk group of
diabetic patients (odds ratios: 0.59 vs 1, Po0.01, Table 4).
As for diabetics, patients that have previously experienced
renal failure are also particularly vulnerable towards develop-
ing CIN. The separate analysis of this patient group revealed
less renal failures in the ioxaglate-treated group (Figure 1d),
the odds ratio being 0.54 (vs 1 for iodixanol, Po0.01). The
separate analyses of these high-risk patients underscore that
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Figure 1 | Renal failure and dialysis in patient groups. (a) Kaplan–Meier curve illustrating percentage of patients being re-hospitalized
with a primary diagnosis of renal failure. At time ‘0’, these patients had been given CM for coronary procedures. The diagnosis was documented
upon releasing the patient from the clinic. Iodixanol solid line (n¼ 45 287), ioxaglate dotted line (n¼ 12 379). As (b), but for the total
diagnosis of renal failure (primary and secondary diagnosis). As (c), but for dialysis treatment. (d) As (a), but for those patients which
had previously experienced renal failure. (e) As (a), but for one hospital that changed from ioxaglate (1991–1999) to iodixanol (2001–2003).
Iodixanol solid line (n¼ 4765), ioxaglate as dotted line (n¼ 6296). (f) Long time follow-up of clinically significant renal failure as primary
or secondary diagnosis after coronary procedures in relation to contrast medium, iodixanol solid line (n¼ 54 616), iohexol short dotted line
(n¼ 6854), and ioxaglate as long dotted line (n¼ 24 479).
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an unbalance in covariates ‘diabetes’ (more often in the
ioxaglate group) or ‘previous renal failure’ (more often in the
iodixanol group) had no effect on the basic outcome.
Intriguingly, the clinics that had shifted CM from to
iodixanol experienced an increase in the occurrence of
clinically significant renal failure (Figure 1e). It is unlikely
that the patient profiles, treatment of patients, and the
criteria for diagnosing renal failure should have changed in
these clinics from one year to the other. Rather it appears as if
the type of CM causes the difference in the occurrence of
clinically significant renal failure.
We also performed a multivariable regressive approach to
properly compensate for differences in covariates (Tables 3
and 4). This is possible as the sample size is very large. Thus,
the independent risk for clinically significant renal failure
caused by the single risk factor was quantified and
compensated for.
As an indication for the severity of the interventions, the
proportion of stenting within the patient groups and the
average amount of stents were analyzed. As seen in Table 2,
these values were similar between the groups. However, the
slightly higher proportion of stenting in the ioxaglate group
is significantly different.
Analysis 1990–2003 (group 5)
In total 86 334 patients were studied from 1990 to 2003.
Iohexol used in 6,898 subjects. In 1990, iohexol was
frequently used, whereas after 2000, there were no more
clinics using this CM.
In later years, the indication for giving CM may have
changed and patients at higher risk for CIN may have been
given CM. Furthermore, hospitalization with a renal failure
diagnosis in all is increasing with time. In Sweden, the
numbers of hospitalizations with this diagnosis have
increased by 26% between 1998 and 2003.12 These restric-
tions must be kept in mind when interpreting the data for
iohexol-treated patients in group 5. Treatment with this third
CM caused a similar incidence of clinically significant renal
failure within 3 months as ioxaglate (0.9 vs 0.8% for ioxaglate
and 1.6% for iodixanol, Po0.001).
Figure 1f is a long-term follow-up over 12 years. The
marked increase of renal failure diagnosis following CM
treatment is apparent during the first weeks. In the
beginning, iodixanol leads to a much higher diagnosis rate
of clinically significant renal failure. This difference (2% vs
1%) then remains stable over the next years. The constant
slope after the immediate high-risk period indicates that the
following risk to develop clinically significant renal failure is
constant among the groups. In other words, iodixanol causes
a greater risk for developing clinically significant renal failure
during the first weeks after coronary interventions. After this
period of high risk, the patients of all groups had the same
risk for developing clinically significant renal failure (the
slopes of the curves are very similar).
Hydration, plasma creatinine, and CM volumes
All sites were contacted to determine specific hydration
policies. These sites had hydration protocols and used these
at least since 2000. Site-specific differences were detected with
regard to fluids used (e.g., Ringer’s solution or saline) and
route of administration (p.o. or i.v.). However, we did not
find any systematic differences between the ioxaglate using
sites and the centers giving iodixanol. Thus, any differences
seen are unlikely accounted for by various hydration regimens.
Table 3 | Re-hospitalizations with a renal failure diagnosis
and start of dialysis after coronary angiography or PCI in
relation to CM
Time period
2000–2003
Variable Ioxaglate Iodixanol P-value
N 12 440 45 485 NS
A/main or secondary diagnosis
Within 1 week 50 (0.4%) 339 (0.7%) o0.001
Within 1 month 71 (0.6%) 551 (1.2%) o0.001
Within 3 months 97 (0.8%) 753 (1.7%) o0.001
B/Main diagnosis
Within 1 week 2 (0.02%) 33 (0.07%) 0.022
Within 1 month 4 (0.03%) 74 (0.2%) o0.001
Within 3 months 10 (0.1%) 141 (0.3%) o0.001
C/Start of dialysis
Within 1 week 0 (0.0%) 10 (0.02%) 0.098
Within 1 month 3 (0.02%) 46 (0.1%) 0.009
Within 3 months 9 (0.1%) 79 (0.2%) 0.010
CM, contrast media; NS, nonsignificant; PCI, percutaneous coronary interventions.
The time refers to the release of patients.
Table 4 | Multivariable analysis of hospitalizations after PCI/
coronary angiography in centers with iodixanol or ioxaglate
as used CM
Renal failure diagnosis Odds ratio (95% CI) P-value
Main or secondary diagnosis
Iodixanol 1 — —
Ioxaglate 0.48 (0.39–0.58) o0.001
With previous renal failure
Iodixanol 1 — —
Ioxaglate 0.54 (0.34–0.86) 0.009
With diabetes
Iodixanol 1 — —
Ioxaglate 0.59 (0.40–0.86) 0.007
Only PCI
Iodixanol 1 — —
Ioxaglate 0.66 (0.46–0.93) 0.019
Main diagnosis
Iodixanol 1 — —
Ioxaglate 0.25 (0.13–0.48) o0.001
Start of dialysis
Iodixanol 1 — —
Ioxaglate 0.48 (0.24–0.96) 0.039
CM, contrast media; PCI, percutaneous coronary interventions.
A logistic regression model was used for compensations of differences in back-
ground and procedures (see Table 2). *n=number of patients included in the analysis
where all cofactors are specified.
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Doses of CM and plasma creatinine levels are documented
in the Swedish Coronary Angiography and Angioplasty
Registry (SCAAR) register since 2005. The data from these
patients will be provided by the hospital discharge register by
the second half of 2007.
During 2005 at the studied hospitals, 8100 patients have
been recorded and do not indicate any significant differences
in volume given (iodixanol: 138789 ml vs iogloxate:
1477105 ml; the median values were 110 and 120 ml,
respectively). Moreover, the baseline creatinine values are
comparable (iodixanol: 91754 mmol/l vs ioxaglate:
100756 mmol/l; median values: 83 mmol/l vs 92 mmol/l,
respectively). Thus similar volumes of iodixanol and
ioxaglate are given per intervention and the patients seem
to have comparable renal function before the intervention.
DISCUSSION
The overall risk of developing clinically significant renal
failure 3 months after giving CM for coronary interventions
is between 1 and 2%. This is around one magnitude of order
greater than an aged and gender-matched cohort of Sweden
during the same years (0.131% p.a.). Patients receiving
iodixanol had a higher risk of being re-hospitalized with a
diagnosis of renal failure. The corresponding risk for patients
receiving ioxaglate was significantly less (Figure 1, Table 4).
In accord, subsequent dialysis after coronary procedures
occurred more often in the iodixanol-treated group. These
differences were statistically significant as confirmed by
multivariable analysis that compensates differences in the
background characteristics.
Solomon et al.13 have shown that even a minor increase in
serum creatinine following CM use increases hospital stay on
average by 4 days. Beyond the implications for public health,
the choice of CM may have economical relevance. In districts
of those hospitals using iodixanol, renal failure is diagnosed
16.7% more often than in the districts with hospitals using
ioxaglate.12 A large randomized prospective survey is
required to fully elucidate the impact of various CM types
on renal failure and the consequences for public health.
A third CM, iohexol, was commonly used in the beginning
of the 1990s. Comparison of iohexol with the other two CM
is difficult owing to substantial time effects. We therefore
focus the analysis on the comparison between iodixanol and
ioxaglate. However, it may still be appreciated that the risk to
develop clinically significant renal failure seems to be
significantly lower for the patients treated with this older
CM than for those treated with the next generation of CM,
iodixanol (Figure 1f). It seems that the CM with lower
viscosities have a reduced risk for developing clinically
significant renal failure and dialysis.
The present findings seemingly contrast to two previous
investigations. The first study,14 suggested that iodixanol may
be slightly less nephrotoxic than iohexol. In the second study,
NEPHRIC, a considerable benefit for iodixanol vs iohexol
was found for diabetic patients.9 Comparing the presented
findings with NEPHRIC and other studies is difficult, if not
altogether impossible, as the end points and numbers are
very different. Here we analyzed a very large database and
used clinically significant renal failure and dialysis as end
points. The NEPHRIC study involved diabetic patients only,
as these are at higher risk for developing renal failure.
Therefore, as a subset, diabetic patients were analyzed
separately in the present study (Table 4). When only
analyzing these diabetic patients, the outcome was as seen
for the nondiabetic patients: iodixanol-treated patients
experienced clinically significant renal failure twice as often
as the patients of the ioxaglate group. Accordingly, the
odds ratio was significantly higher for iodixanol (Table 4).
This subset analysis suggests that the higher incidence of
clinically significant renal failure caused by iodixanol is
independent from the distribution of diabetic patients among
the groups.
The perception that iodixanol is of less damage to the
kidney than other CM came about in 2003, when NEPHRIC
was published. This is the last year of our analysis, but
excluding this year does not affect the general outcome of the
present study (data not shown).
Methodology and validation of the study
The shape of the Kaplan–Meier curves (Figure 1) may
surprise. CIN is considered to be an acute phenomenon
occurring during the first 3 days after CM is given.4 After less
than three weeks, plasma creatinine levels usually return to
normal. In the present study, the diagnosis of renal failure
was followed up for 3 months. Instead of only finding an
immediate increase during the first days, the diagnosis renal
failure leveled off rather late, that is, after 2 weeks–3 months.
This has two obvious reasons: (1) A hospital discharge
register was used. Thus, the final diagnosis was documented
after the patient had been released from the clinic. This
causes a considerable time delay. (2) Often there is a
considerable delay until patients are reintroduced to the
hospital. Taken together, these two factors cause a consider-
able lag, as seen in Figure 1.
In Figure 1f, the follow-up for patients until 12 years is
shown. As for the other panels of Figure 1, the origin (i.e.,
time 0) refers to the application of CM. After the initial sharp
increase in the diagnosis of renal failure during the first
weeks, the risk for developing clinically significant renal
failure is the same for all three groups (the three regressions
run parallel). These linear slopes reflect the intrinsic risk for
developing clinically significant renal failure. As the slopes do
not differ among the groups of CM, there are no a priori
differences in the intrinsic risk for developing clinically
significant renal failure. The slopes of the curves indicate the
risk for developing renal failure. Thus, the risk for renal
failure remains constant for the years following the cardiac
intervention.
Taken together, Figure 1f suggests that the CM given at the
occasion of the coronary intervention causes an initial
increase in the occurrence of clinically significant renal
failure. Afterwards, when this challenge is over, the individual
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groups once again take on the same risk for clinically
significant renal failure.
It appears to be the CM itself that causes the higher risk of
renal damage. This interpretation is underscored by the
clinics that changed CM to iodixanol. Once iodixanol was in
use, the risk for clinically significant renal failure and the
need for dialysis dramatically increased (Figure 1e). There is
no indication that these clinics shifting to iodixanol changed
the guidelines for diagnosing renal failure or that they
suddenly recruited more patients at risk for renal failure. The
CM itself causes this effect. However, it may be argued, that
more patients at risk were treated in clinics using iodixanol.
The contrary is true for diabetic patients (Table 2), but
indeed the iodixanol-treated group contained larger numbers
of renal failure. Therefore, another subset was formed
including only these patients that had previously been
diagnosed with renal failure (Table 4, Figure 1d). This
procedure eliminates the sample bias. When only looking at
patients with previous renal failure, the odds ratio remains
significantly lower for ioxaglate (0.54) than for iodixanol
(1, Po0.01). Thus, again, the outcome of this study cannot be
explained by more high-risk patients receiving iodixanol than
ioxaglate. Taken together, many lines of evidence suggest that
the baseline characteristics are comparable for the ioxaglate
and iodixanol groups. Differences remain regarding the
proportion of patients with previous renal failure. Logistic
regression analyses and subset analyses of this high-risk
group showed that this difference did not influence the
outcome. If there were any undetected differences in group
randomization, it is obvious that treatment with iodixanol
was not successful in preventing CIN in these subjects.
Pathophysiological considerations
This study cannot clarify reasons for the differences in renal
failure occurrence. Among the several discussed mechanisms
involved in CIN (for review see Persson et al.15), CM viscosity
may deserve some consideration in understanding the higher
incidence of renal failure in patients treated with iodixanol.
Viscosity of the nonionic dimers is high which may be
explained by various parameters, such as the so-called
volumic fraction of the solute, that is, the volume of solvent
occupied by hydrated molecules of the solute. This causes
specific inter-molecular interactions (e.g., stacking) and,
indirectly, influences shape and hydrophilicity.
Renal fluid uptake traps CM in the tubules, causing
dramatic increases in fluid viscosity.15 Iodixanol is very
viscous (Table 1) and will not give rise to an osmotic diuresis
as other hyperosmolar compounds. Thus, iodixanol becomes
particularly concentrated upon renal tubular passage. Fluid
viscosity is a known risk factor for renal damage, for example,
it is one critical factor for the crush kidney, where excessive
protein levels are observed and lead to kidney damage. Also,
high viscous solutions such as molecular dextran have been
shown to cause kidney damage.16 However, many other
factors such as cytotoxicity and apoptosis must be considered
as further possible mediators.
Conclusion
In this study, we find no indication that use of the iso-
osmolar CM iodixanol results in less damage to the kidney
than use of the higher osmolar CM ioxaglate. In fact, the
contrary seems to be the case.
MATERIALS AND METHODS
Patients
This study was carried out of data from Swedish hospitals that only
use one specific contrast medium compound. The SCAAR
documents patients from all centers performing PCI and/or
coronary angiography in Sweden. By 31 December 2003, informa-
tion from 181 446 coronary procedures (81 677 PCIs and the rest
only diagnostic catheterizations) in 127 098 patients had been
collected in SCAAR. The patients were classified according to the
CM given. Parameters such as age, gender, indication of the
procedure, the extent of the coronary disease, and complications
were recorded in the register. For the PCI-treated patients, also
information about coronary risk factors, for example, diabetes,
previous coronary interventions, and procedural data were collected.
Information regarding hydration strategy was not recorded in the
SCAAR, the type and amount of CM as well as baseline plasma
creatinine has been added in 2005.
The following groups were studied:
1. Patients receiving either iodixanol or ioxaglate from 2000 to 2003
2. Only diabetic patients of the total group 2000–2003
3. Only patients with previous renal failure of the total group
2000–2003
4. Only patients undergoing PCI of the total group 2000–2003
5. Patients receiving either iodixanol or ioxaglate, or iohexol from
1990 to 2003
Until the year 2000, iohexol was continuously replaced by other
CM, thus, there is a potential time effect in the subanalysis of
iohexol (group 5). After 2000, iohexol was no longer given regularly.
Conversely, the relative use of the other two CM was quite constant,
with a use of ioxaglate between 20.4 and 23.0%. The main analysis
shown in Tables 2–4 only includes the time stable data from 2000 to
2003.
In Sweden, hospitals performing coronary procedures only use one
specific CM. Three hospitals switched over from iohexol to iodixanol
(between 1995 and 1997), and one hospital from ioxaglate to
iodixanol in 2000. Three hospitals switched over from iohexol to
iodixanol (between 1995 and 1997), and one hospital from ioxaglate
to iodixanol in 2000. During the transition year no patients from these
hospitals were included in the analysis to avoid incorrect grouping.
The diagnosis of renal failure was taken from the ‘Hospital
Discharge Register’, a national register run by the Swedish
government.17,18 By combining the SCAAR and the Swedish all-
national ‘Hospital Discharge Register’ hospitalizations with diag-
nosis of renal failure (main and secondary) and of required dialysis
of the patients could be followed up to the 31 December 2003. The
definition of renal insufficiency was according to ICD-9 (585 or 586)
and ICD-10 (N14, N17–19, or N99) and of dialysis ICD-9 (V56A or
V45B) and ICD-10 (Z49 or Z99.2) or procedure code v9211, v9212,
v9200, v9531, or v9532. Diabetes was defined as recorded in SCAAR.
If the information was missing in SCAAR, the patients were defined
as having diabetes if there was any previous hospitalization with a
diagnosis of diabetes mellitus.
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Patients with documented previous dialysis were excluded in the
analysis of subsequent dialysis after the coronary procedures.
The combination of the two registers was carried out in
cooperation with the Swedish National Board of Health and Welfare
and was approved by the local ethics committee at the University of
Uppsala.
The study complied with the Declaration of Helsinki Principles.
Data analyses
Two hospitals, one with an iodixanol policy, the other using
ioxaglate were examined to verify the exclusiveness of the CM given.
In total, 9305 patients from our study were treated in these centers.
In all cases the predicted CM had been given.
One-way analysis of variance was used for continuous variables
and the Pearson w2 test for categorical data. Kaplan–Meier curves
depict hospitalizations with a diagnosis of renal insufficiency within
3 months from the last coronary procedure. The time axis refers to
the date when these patients left the hospital, that is, at the time
where the diagnosis was documented after having been treated.
Multivariable Logistic regression analyses were performed to
evaluate the effect of CM strategy on the renal insufficiency after the
coronary procedures. In our model, we entered relevant clinical
background variables as specified in Table 2. Multivariable analyses,
also compensated for differences in these covariates.
Po0.05 was considered statistically significant. Data processing
and statistical analyses were performed by SPSS 11.5.1.
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